What were the revenue growth rates and margins for the 9 months, and how do they compare year‑over‑year and to the prior quarter? | COLO (Aug 08, 2025) | Candlesense
COLO

What were the revenue growth rates and margins for the 9 months, and how do they compare year‑over‑year and to the prior quarter?

Answer

The news release you provided only announces the upcoming conference call for Coloplast A/S’s 9‑month (9M) 2024/25 interim results and the availability of a presentation. It does not contain the actual financial figures—such as revenue amounts, growth rates, or margin percentages—for the 9‑month period, nor does it give any comparative data (year‑over‑year or quarter‑over‑quarter).

Therefore, based solely on the information in the announcement, I cannot report the revenue growth rates or margins for the 9‑month period, nor how they compare to the prior year or the previous quarter.

If you have access to the full earnings release (e.g., the PDF or the presentation that will be posted on Coloplast’s website) or can provide those specific figures, I would be able to analyze and compare the numbers as requested. Otherwise, you may need to wait until the detailed results are published later on 19 August 2025 (around 07:30 CEST) and then review the accompanying presentation or press release for the required metrics.

Other Questions About This News

What is the current free cash flow generation and its impact on planned share buy‑backs or capital allocation? Are there any upcoming catalysts or events (e.g., regulatory approvals, M&A activity, conferences) that could influence the stock price in the near term? How did the 9M 2024/25 earnings compare to analyst expectations and consensus forecasts? Are there any changes to the dividend policy or payout ratio following the interim results? What are the expectations for the upcoming FY 2025/26 guidance, especially regarding the product pipeline and upcoming product launches? Did management comment on any macro‑economic or regulatory risks that could affect future performance? Which Business Units (e.g., Colostomy, Urology, Wound Care) drove the performance, and were there any notable segment trends? What is the outlook for full‑year 2024/25 earnings and guidance – any revisions to revenue, EBITDA, or EPS forecasts? How does the current valuation (P/E, EV/EBITDA) compare to key competitors in the medical device sector after this release? How did currency fluctuations (euro, US $) affect the reported results, and what hedging strategies are in place? What is the expected impact of the 9M results on the stock’s technical indicators (e.g., support/resistance levels) in the short‑term?